<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref026">
 <label>26</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Foster</surname>
   <given-names>GR</given-names>
  </name>, 
  <name>
   <surname>Dore</surname>
   <given-names>GJ</given-names>
  </name>, 
  <name>
   <surname>Wang</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Grebely</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Sherman</surname>
   <given-names>KE</given-names>
  </name>, 
  <name>
   <surname>Baumgarten</surname>
   <given-names>A</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies</article-title>. 
  <source>Drug Alcohol Depend</source>. 
  <year>2019</year>
  <day>1</day>;
  <volume>194</volume>:
  <fpage>487</fpage>â€“
  <lpage>94</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.11.007</pub-id>
  <?supplied-pmid 30529905?>
  <pub-id pub-id-type="pmid">30529905</pub-id>
 </mixed-citation>
</ref>
